Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer (NCT04050436)

🧪 Interventions in This Study

• Cemiplimab (DRUG)
• RP1 (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (56 Sites)

Showing the first 25 of 56 sites.

• University of California San Diego — La Jolla, California
• University of California Los Angeles — Los Angeles, California
• Stanford University — Stanford, California
• University of Colorado Cancer Center — Aurora, Colorado
• University of Miami Health System — Miami, Florida
• Orlando Health UF Health Cancer Center — Orlando, Florida
• Moffitt McKinley Outpatient Center — Tampa, Florida
• Winship Cancer Institute of Emory University — Atlanta, Georgia
• John Theurer Cancer Center at Hackensack Univeristy Medical Center — Hackensack, New Jersey
• Memorial Sloan Kettering Cancer Center — New York, New York
• University Of North Carolina at Chapel Hill — Chapel Hill, North Carolina
• Ohio State University Comprehensive Cancer Center — Columbus, Ohio
• Prisma Health Cancer Institute — Greenville, South Carolina
• MD Anderson Cancer Center — Houston, Texas
• Chris O'Brien Lifehouse — Camperdown, New South Wales
• Cancer Care Wollongong Pty Limited — Wollongong, New South Wales
• Tasman Oncology Research Ltd — Southport, Queensland
• Monash Medical Centre — Clayton, Victoria
• Peter MacCallum Cancer Centre — Melbourne, Victoria
• The Alfred Hospital — Melbourne, Victoria
• Sir Charles Gairdner Hospital — Nedlands, Western Australia
• Multiprofile Hospital for Active Treatment - Uni Hospital" OOD Department of Medical Oncology — Panagyurishte,
• "Complex Oncology Center - Plovdiv" EOOD Department of Medical Oncology and Cutaneous Cancer Diseases " — Plovdiv,
• Sunnybrook Health Science Centre — Toronto, Ontario
• CHU Besancon - Hopital Jean Minjoz — Besançon,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Cutaneous Squamous Cell Carcinoma

• Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma — Houston, Texas
• Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy — Boston, Massachusetts
• TIL Therapy in cSCC and MCC — Boston, Massachusetts
• A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma — Albury, New South Wales
• A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer — Aurora, Colorado

Explore by condition: All Cutaneous Squamous Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.